Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Fineline Cube Jul 10, 2026
Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia

Fineline Cube Jul 10, 2026
Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Fineline Cube Jul 10, 2026
Company Drug

Johnson & Johnson’s Talquetamab and Daiichi Sankyo’s Enhertu Eye Priority Review in China

Fineline Cube Feb 5, 2024

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J, NYSE:...

Company

Biogen Discontinues Aduhelm Development, Redirects Focus to Other Alzheimer’s Therapies

Fineline Cube Feb 5, 2024

Biogen (NASDAQ: BIIB) has announced its decision to discontinue the development and commercialization of its...

Company

Beckton Dickinson’s Q1 Results Affected by Volume-Based Procurement, Life Sciences Growth

Fineline Cube Feb 5, 2024

US-based medical technology company Beckton Dickinson (BD; NYSE: BDX) has reported its financial results for...

Company Drug

SciClone and Menarini File for Import License of Antibacterial Drug Vaborem in Macau

Fineline Cube Feb 5, 2024

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that its Italy-based strategic partner Menarini has submitted...

Company Deals

Baidu Health Partners with Souyao to Boost Offline Pharmacy Services in China

Fineline Cube Feb 5, 2024

Baidu Health has entered into a partnership with Beijing-based pharmaceutical business service provider Souyao. The...

Company

AbbVie Reports $54.3 Billion in 2023 Revenues Amid Humira Erosion and Segment Variability

Fineline Cube Feb 4, 2024

AbbVie (NYSE: ABBV) reported revenues of $54.3 billion for 2023, reflecting a 5.9% year-on-year decline...

Policy / Regulatory

US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions

Fineline Cube Feb 4, 2024

A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract...

Company Drug

Biotech Pharmaceutical Secures Approval for Nimotuzumab in Head and Neck Cancer Treatment

Fineline Cube Feb 4, 2024

Sino-Cuban joint venture Biotech Pharmaceutical Limited (BPL) has secured another indication approval in China for...

Company Drug

BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity

Fineline Cube Feb 4, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) reported a 2% year-on-year contraction in 2023 revenues, excluding...

Policy / Regulatory R&D

China Reports Over 4.8 Million New Cancer Cases in 2022 Amid Rising Incidence and Mortality Rates

Fineline Cube Feb 4, 2024

China’s National Cancer Center (NCC) has released the latest national cancer statistics, approved by the...

Company Deals

Johnson & Johnson’s Kenvue Partners with Tencent for Integrated Health Services in China

Fineline Cube Feb 4, 2024

Johnson & Johnson (J&J, NYSE: JNJ)’s consumer health spinoff Kenvue and its Chinese partner Tencent...

Company Drug

Chongqing Genrix Biopharmaceutical Gets NMPA Clearance for IL-4Rα mAb Candidate GR1802

Fineline Cube Feb 4, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has announced that it...

Company Deals Drug

Inmagene Biopharmaceuticals Secures Exclusive License for HutchMed’s Drug Candidates IMG-007 and IMG-004

Fineline Cube Feb 4, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that Sino-US biotech Inmagene Biopharmaceuticals has...

Company Legal / IP

Luye Pharma’s Paliperidone Palmitate NDA Avoids Patent Lawsuit, Clears Path for FDA Approval

Fineline Cube Feb 4, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that the New Drug...

Company Deals

Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics

Fineline Cube Feb 4, 2024

Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in...

Company Deals Drug

China Medical System Reclaims Rights to Velphoro from WinHealth in Greater China

Fineline Cube Feb 4, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a rights assignment agreement with...

Company Drug

Sichuan’s Ancocare Gets FDA Green Light for Phase I/III Study of Oncolytic Virus in Neuroblastoma

Fineline Cube Feb 4, 2024

Sichuan-based Flavivirus technology platform developer Ancocare has announced that it has received approval from the...

Company

Siemens Healthineers Posts 5.7% Q1 2024 Sales Growth, Exceeds Pre-Pandemic Levels

Fineline Cube Feb 4, 2024

Siemens Healthineers AG (ETR: SHL), based in Germany, has released its quarterly report for the...

Company Drug

Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products

Fineline Cube Feb 4, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest...

Company Deals

Teva Pharmaceuticals Initiates Spin-off of TAPI Unit, Targeting 2025 for Completion

Fineline Cube Feb 2, 2024

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) a transnational generic drugs giant with Israeli and U.S....

Posts pagination

1 … 431 432 433 … 693

Recent updates

  • PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates
  • Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia
  • Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise
  • Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics
  • Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Company Drug

Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia

Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.